Beyond THC and CBD: The Promising Medical Potential of CBG

Introduction Cannabigerol (CBG), a non-psychoactive cannabinoid found in the Cannabis sativa plant, is gaining attention in the scientific community for its potential therapeutic benefits. Unlike its more famous counterparts, THC and CBD, CBG is often referred to as the "mother of all cannabinoids" due to a common misconception about its role as a precursor from which other cannabinoids are synthesized (these cannabinoids are synthesized from CBGA, the acidic form of CBG, from which CBG is itself synthesized). This article delves into the effects, benefits, and legal status of CBG, with a particular focus on its interaction with various receptor sites in the human body.

The Endocannabinoid System and CBG The endocannabinoid system (ECS) is a complex cell-signaling system that plays a key role in regulating a wide range of functions and processes, including sleep, mood, appetite, memory, and reproduction. It is composed of endocannabinoids, receptors, and enzymes. CBG, like other cannabinoids, interacts with this system, but it does so in a unique way.

CBG has a low affinity for CB1 and CB2 receptors, the primary receptors in the ECS. However, it acts as an antagonist of the CB1–CB2 heteromer, a complex that forms when CB1 and CB2 receptors come into close proximity. This interaction may have implications for the modulation of the ECS and the potential therapeutic applications of CBG. In addition to its known affects with the endocannabinoid system, CBG also interacts in a few key ways with other receptor sites in the body:

5-HT1A Receptor

The 5-HT1A receptor is a subtype of the serotonin receptor, which is widely distributed throughout the brain and plays a key role in the regulation of mood and cognition. CBG has been shown to have a high affinity for this receptor, suggesting potential antidepressant and anti-anxiety effects. A study found that CBG exhibits a strong affinity for the 5HT1A receptor, acting as a partial agonist. This interaction leads to a cascade of immediate physiological effects, including modulation of neurotransmission, regulation of mood, and control of stress responses. These effects are primarily due to the role of the 5HT1A receptor in the serotonergic system, which is crucial for maintaining mental health.

The interaction between CBG and the 5HT1A receptor also opens up potential medicinal uses. For instance, a study in 2020 suggested that CBG could be used in the treatment of anxiety and depression due to its ability to modulate serotonin levels. Additionally, a review by Russo and Marcu (2017) highlighted the potential of CBG in alleviating symptoms of conditions such as Parkinson's disease and migraines, where the 5HT1A receptor is known to play a significant role.

α-2 Adrenoceptor

PPARγ

GPR55

TRP Channels

The FDA and Cannabinoids The U.S. Food and Drug Administration (FDA) regulates cannabis-derived compounds as it does any other FDA-regulated products. However, the FDA has also stated that ingredients derived from parts of the cannabis plant that do not contain THC or CBD might be able to be marketed as dietary supplements. For example, the FDA has issued a GRAS (Generally Recognized as Safe) certification for three hemp-related products, including hemp-seed oil, indicating that some parts of the cannabis plant are safe to consume or study without the need for an Investigational New Drug (IND) application or additional legal restrictions.

The FDA's regulations distinguish between parts of the cannabis plant that are generally recognized as safe and may be consumed or studied without the need for an IND (such as hemp seed oil), and those that are drugs by definition and must be treated as such (like isolated CBD). However, the FDA has not provided clear guidance on substances that contain cannabinoids other than THC and CBD, particularly when those substances contain only trace elements of both THC and CBD.

When it comes to CBG, it's important to examine the FDA’s current positioning, the reasoning behind it, and the safety information and research that is presently available. The FDA's primary concern with potential contaminants in hemp seed-derived ingredients is THC and CBD. However, the GRAS approval and previous responses indicate the potential for other cannabinoids in legal hemp seed products. This aligns with research that has found a statistically significant amount of cannabinoids in GRAS hemp seed oils, including CBG.

The FDA is currently evaluating the regulatory frameworks that apply to certain cannabis-derived products that are intended for non-drug uses. While CBG products as a whole appear to remain in a legislative gray area until the FDA is able to collect additional information and issue a determination, it is clear that their guidelines are focused on product safety as well as the concentration, if any, of THC and CBD in the product. They have stated they are committed to setting sound, science-based policy and are seeking evidence, based in clinical science, to make determinations on non-THC, non-CBD cannabis-derived products. It is this determination that Formula30A Cannabigerol, a full-spectrum extract naturally containing zero percent THC from seed to end product and only trace amounts of CBD, was approved by an Independent Review Board for clinical study in healthy humans. This commitment by the FDA is underscored by the launch of the Cannabis Derived Products Data Acceleration Plan, which aims to increase the FDA's ability to gather information on the safety of cannabis-derived products, including emerging cannabinoid markets such as CBG.

Conclusion CBG is a fascinating cannabinoid with a unique profile of activity at various receptor sites. Its potential therapeutic benefits, coupled with its non-psychoactive nature, make it a promising candidate for further research and potential therapeutic applications. As our understanding of the endocannabinoid system and the role of cannabinoids like CBG continues to grow, so too does the potential for new, innovative treatments for a variety of conditions.

---

References